 Hoth Therapeutics, Inc. Hoth or the Company NASDAQ: HOTH, a biopharmaceutical company, announced today the closing of its previously announced underwritten public offering of 1,818,182 shares of its common stock, at a price to the public of 2.75 per share. The gross proceeds to Hoth from this offering are expected to be approximately 5.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Hoth. In addition, Hoth has granted the underwriters a 45-day option to purchase up to an additional 272,727 shares of common stock at the public offering price, less underwriting discounts and commissions. Hoth intends to use the net proceeds from the offering for general corporate purposes, including the development of products to prevent Coronavirus COVID-19, working capital, sales and marketing activities, and general and administrative matters. 